|
Pune, Jan 30: A local court has rejected an application seeking injunction against the use of ‘Covishield’ as brandname by the vaccine-maker Serum Institute of India (SII), the company said on Saturday.
Representational Image
SII is producing a coronavirus vaccine named Covishield, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Indian government has purchased 11 million doses of Covishield vaccine.
While the court order was not available immediately, the lawyer of Cutis-Biotech, which had filed the suit, said it would file an appeal in the high court.
Serum Institute applies for trials of another Covid-19 vaccine; hopes to launch Covavax by June 2021
On January…
